Arbutus reported a smaller net loss in Q3 2025 due to significant cost reductions in R&D and G&A expenses. Revenue declined slightly year-over-year, and the company maintained a solid cash position of $93.7M to support ongoing HBV programs.
Net loss reduced to $7.7 million compared to $19.7 million in Q3 2024.
Cash and investments stood at $93.7 million as of September 30, 2025.
Revenue declined to $0.5 million due to reduced royalty income.
R&D and G&A costs fell significantly due to restructuring and focus on core programs.
Arbutus aims to extend its cash runway and continue advancing imdusiran development, while facing reduced revenues and ongoing litigation.
Analyze how earnings announcements historically affect stock price performance